Catabasis Pharmaceuticals Inc. today announced that chief medical officer Joanne Donovan, M.D., Ph.D., will present an overview of CAT-1004, an oral small molecule designed to modulate NF-kB for the treatment of Duchenne Muscular Dystrophy (DMD), at the Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference in Chicago, IL, on June 28, 2014. In addition, Catabasis chief scientific officer and co-founder Michael Jirousek, Ph.D., will present at the 2014 New Directions in Biology and Disease of Skeletal Muscle Conference in Chicago, IL, on June 29, 2014.
Help employers find you! Check out all the jobs and post your resume.
